BBIO BridgeBio Pharma, Inc.

NASDAQ
$76.03

BridgeBio Pharma, Inc. (BBIO) is expected to report earnings on January 28, 2027, after the market close. The consensus earnings estimate is a loss of $0.59 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +4.4% since its last earnings release on October 29, 2026.

BridgeBio Pharma Beat Consensus Estimates
Thursday, October 29, 2026 · 4:01 PM ET
Earnings Date
4th Quarter, Dec 2026
Jan 28
Thursday · 4:00 PM ET
Earnings Whisper
-
vs ($0.59)
Rev est $320.4M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $76.66

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.